Aspirin for Prevention of Preeclampsia

170Citations
Citations of this article
565Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia.

Cite

CITATION STYLE

APA

Atallah, A., Lecarpentier, E., Goffinet, F., Doret-Dion, M., Gaucherand, P., & Tsatsaris, V. (2017). Aspirin for Prevention of Preeclampsia. Drugs, 77(17), 1819–1831. https://doi.org/10.1007/s40265-017-0823-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free